MoonLake: landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis

 

• First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody^® to report positive topline results in support of potential best-in-class profile
• Primary endpoint ACR50 met with up to 47% (p<0.01 versus placebo) of patients on sonelokimab achieving ACR50 as early as week 12
• All key secondary endpoints met including up to 77% (p<0.001 versus placebo) of patients on sonelokimab achieving PASI90 as early as week 12
• Other secondary endpoints also reached statistical significance at week 12, including endpoints focused on deep tissue inflammation, Minimal Disease Activity (MDA) and patient reported outcomes
• High threshold outcomes, including ACR70 and PASI100, continue to improve beyond week 12, consistent with previous studies of sonelokimab
• Discontinuation rate below 4% and safety results of sonelokimab consistent with previously reported studies with no new safety signals
• The top-line data will be discussed on Monday 6 November, at 2pm CET/8am ET, via webcast 

These topline data will be discussed on Monday November 6, 2023 at 2pm CET/8am ET before the Nasdaq market opens, via webcast at:

https://edge.media-server.com/mmc/p/bp43a4xr

A replay of the webcast and the presentation document will be made available at https://ir.moonlaketx.com.

https://www.biospace.com/article/releases/moonlake-immunotherapeutics-announces-landmark-phase-2-results-for-nanobody-sonelokimab-in-active-psoriatic-arthritis/